Tumor cytotoxicity induced by modulators of the CXCR4 receptor
US7312305B2 · kind B2 · utility
1Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2003 |
| Grant date | Dec 25, 2007 |
| Priority date | — |
| Expiry date | May 2, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/162
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.